Renata Valuation Multiples

Renata Overview

About Renata

Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.

Founded

1972

HQ

Employees

13.2K

Website

renata-ltd.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: $354M

EBITDA: $49M

EV

$533M

Valuation Multiples

Multiples.vc

Start free trial

Renata Financials

Renata reported last fiscal year revenue of $354M and EBITDA of $49M.

In the same fiscal year, Renata generated $145M in gross profit, $49M in EBITDA, and $18M in net income.

Renata P&L

In the most recent fiscal year, Renata reported revenue of $354M and EBITDA of $49M.

Renata expects next 12-month revenue of XXX and NTM EBITDA of XXX

Renata Stock Performance

Renata has current market cap of $402M, and enterprise value of $533M.

Renata's stock price is $3.50.

Renata Valuation Multiples

Renata trades at 1.5x EV/Revenue multiple, and 10.9x EV/EBITDA.

Renata Financial Valuation Multiples

As of April 11, 2026, Renata has market cap of $402M and EV of $533M.

Equity research analysts estimate Renata's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Renata has a P/E ratio of 21.9x.

Renata Margins & Growth Rates

Renata's revenue in the last fiscal year grew by 9%.

Renata's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

Renata's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Renata's rule of X is 46% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Renata Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Renata M&A Activity

Renata acquired XXX companies to date.

Last acquisition by Renata was on XXXXXXXX, XXXXX. Renata acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Renata Investment Activity

Renata invested in XXX companies to date.

Renata made its latest investment on XXXXXXXX, XXXXX. Renata invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).